Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-17A


Brief Information

Name:Interleukin 17A
Target Synonym:Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8),CTLA8,IL17A,Interleukin 17A,Cytotoxic T-Lymphocyte-Associated Antigen 8,Cytotoxic T-Lymphocyte-Associated Protein 8,CTLA-8,IL-17A,IL-17,IL17,Interleukin-17A
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CT8-M5240-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Mouse IL-17A, His Tag (Cat. No. CT8-M5240) stimulates secretion of IL-6 by NIH-3T3 cells. The ED50 for this effect is 2.132-5.005 ng/mL.


Loaded Biotinylated Human IL17A, His,Avitag (Cat. No. ILA-H82Q1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 18.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human IL-17 RA, Fc Tag (Cat. No. ILA-H5257) on Protein A Biosensor, can bind Mouse IL-17A, His Tag (Cat. No. CT8-M5240) with an affinity constant of 20.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Virulizin Approved Aptose Virulizin, Virulizin-2 gamma Mexico Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms null 1997-01-01 Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms Details
Ixekizumab LY-2439821 Approved Eli Lilly And Company 拓咨, Taltz EU Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing Eli Lilly And Company (Ireland) Ltd 2016-03-22 Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Spondylarthritis; Arthritis, Rheumatoid; Psoriasis; Arthritis, Psoriatic; Plaque psoriasis Details
Secukinumab NVP-AIN-457; AIN-457; KB-03303A Approved Novartis Pharma Ag Cosentyx, 可善挺 United States Arthritis, Juvenile; Arthritis, Psoriatic Novartis Pharma Ag 2014-12-26 Psoriasis; Crohn Disease; Plaque psoriasis; Gastroenteritis; Behcet Syndrome; Arthritis; Uveitis; Hidradenitis Suppurativa; Lichen Planus; Parapsoriasis; Asthma; Arthritis, Psoriatic; Tendinopathy; Multiple Sclerosis, Relapsing-Remitting; Graves Ophthalmopathy; Arthritis, Juvenile; Multiple Sclerosis; Lupus Nephritis; Spondylarthritis; Spondylitis, Ankylosing; Arthritis, Rheumatoid; Inflammatory Bowel Diseases; Non-alcoholic Fatty Liver Disease; Giant Cell Arteritis; Diabetes Mellitus, Type 1; Non-radiographic axial spondyloarthritis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
UCB-0159 UCB-0159 Phase 1 Clinical Ucb Sa Autoimmune Diseases Details
CJM-112 CJM-112 Phase 2 Clinical Novartis Pharma Ag Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Myeloma; Multiple Sclerosis; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
HY-1770 HY1770; HT-17; HT17; HY-1770 Phase 1 Clinical Suzhou Pharmavan Co Ltd Plaque psoriasis Details
BAT-2306 Phase 1 Clinical Bio-Thera Solutions Ltd Autoimmune Diseases; Psoriasis; Plaque psoriasis Details
JNJ-61178104 JNJ-61178104 Phase 1 Clinical Janssen Global Services Llc Autoimmune Diseases Details
JNJ-63823539 JNJ-63823539 Phase 1 Clinical Janssen Global Services Llc Arthritis, Rheumatoid Details
COVA-322 COVA-322 Phase 2 Clinical Covagen Psoriasis Details
Vidofludimus 4SC-101; SC-12267 Phase 2 Clinical 4sc Ag Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease Details
IMU-935 IMU-935 Phase 1 Clinical Immunic Ag Prostatic Neoplasms Details
GR-1501 GR-1501 Phase 3 Clinical Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd, Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd Spondylarthritis; Psoriasis; Plaque psoriasis Details
Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) LZM-012; LZM012 Phase 2 Clinical Livzon Pharmaceutical Group Inc, Beijing Kanova Biomedical Technology Co Ltd Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis Details
DMT-310 DMT-310 Phase 2 Clinical Dermata Acne Vulgaris; Rosacea Details
ZL-1102 ZL-1102; CB-001 Phase 1 Clinical Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd Psoriasis Details
Sonelokimab M-1095; ALX-0761; MSB-0010841 Phase 2 Clinical Ablynx Psoriasis Details
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Hashimoto Disease; Healthy Aging Details
Vunakizumab SHR-1314 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Spondylarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Arthritis, Psoriatic; Plaque psoriasis Details
Recombinant humanized anti-IL17A monoclonal antibody(Shanghai CP Guojian) 608 Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Psoriasis; Plaque psoriasis Details
Gumokimab AK-111 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis Details
QX002N QX-002N Phase 2 Clinical Jiangsu Quanxin Biomedical Co Ltd Spondylitis, Ankylosing Details
Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) JS005 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Spondylitis, Ankylosing; Spondylarthritis; Arthritis, Rheumatoid; Psoriasis; Plaque psoriasis Details
Izokibep AFB-035; ABY-035; IMG-020; IMG020 Phase 2 Clinical Affibody Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Uveitis; Plaque psoriasis Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message